A busy session for small-cap healthcare saw Creo Medical (AIM:CREO) dominate the tape with a twin announcement, a £5.5m fundraise and a partial disposal of its core medical business, while Rua Life Sciences (AIM:RUA) reported improving first-half financials as its CDMO build-out begins to bear fruit.
Creo Medical raises £5.5m to back Bipolar range ahead of 2027 launch
Creo Medical Group (AIM:CREO) launched a placing to raise £5.5m in new capital, earmarked to support investment in its Bipolar product range as the company targets a commercial launch in 2027. The fundraise underpins the next phase of development for what management regards as a key growth driver, and the shares responded sharply, rising 27.38% to 14.49p on the day's combined newsflow.
Creo Medical unit's CEO acquires 49% stake at carrying value
Alongside the placing, Creo Medical announced that the CEO of its Creo Medical operating subsidiary, Luis Collantes, is acquiring a 49% stake in that unit in a partial buyout. The terms set an indicative enterprise value in line with the business's carrying value, meaning no write-down is implied. The transaction keeps majority control with the listed group while aligning the unit's leadership directly with its equity, a structure that reduces cash burn at the parent level while retaining operational continuity ahead of the Bipolar launch.
Rua Life Sciences reaches earnings breakeven on higher first-half revenue
Rua Life Sciences (AIM:RUA) reported higher first-half revenue and an earnings breakeven for the period, marking a meaningful step forward for the group after two years of investment-heavy activity. Chairman Bill Brown highlighted progress across the CDMO business, the funding of RUA Structural Heart, and the integration of acquired business Abiss as the foundations for the improved result. The shares added 3.81% to 21.8p on the update.
